Renew Biopharma Renew Biopharma CEO and Co-Founder Michael Mendez (Photo: Business Wire)
Home » Health and medicine » Renew Biopharma Announces Landmark Patent in Cannabinoid Biosynthesis; CEO to Speak Today at SynBioBeta

Renew Biopharma Announces Landmark Patent in Cannabinoid Biosynthesis; CEO to Speak Today at SynBioBeta

SAN FRANCISCO–(BUSINESS WIRE)–Renew Biopharma, a pre-clinical startup drug company developing new, proprietary small molecules to improve human health — focused particularly on neurotherapeutics — today announced a new landmark patent covering the extensive enzyme engineering of the key step for the production of cannabinoids and cannabinoid derivatives using microbial biosynthesis.

This key step is governed by the enzyme that produces CBGA, the precursor to most cannabinoids, including THC and CBD.

The new patent breaks up what was recently cited in Nature as “the log jam” to large-scale microbial cannabinoid biosynthesis. While other cannabinoid biosynthesis companies have employed enzymes derived from the Cannabis plant, their plant-derived enzymes are sub-optimal for microbial production.

Renew, on the other hand, has adopted a novel enzyme from a bacterial origin and has engineered it to outperform the plant enzymes by orders of magnitude. Renew has created more than 300 proprietary variant enzymes (patent doc. WO2019183152) to support best-in-class biosynthesis of both major and minor cannabinoids, as well as cannabinoid derivatives. Renew has used these enzymes to create multiple early drug leads for neurotherapeutics.

Renew also announced that its CEO and co-founder, Michael Mendez, will speak at SynBioBeta 2019 today at 1:30 p.m. (PDT) about Renew’s progress not only with the new patent, but about its work developing a pipeline of novel cannabinoid molecules for neurotherapeutics. Renew’s proprietary technology modifies the cannabinoid biosynthetic pathway by way of synthetic biology and rational enzyme engineering to develop an immense pipeline of cannabinoid derivatives that cross the blood brain barrier and engage specific receptors (not CB1/CB2) in the brain to decrease neuroinflammation.

Said Mendez: “Our new patent describes a technology that overcomes the greatest hurdle that has hindered the cost-effective production of cannabinoids at large scale in microbes. Not only will our novel enzymes enable production of natural cannabinoids like CBD, but they unlock the space to produce thousands of minor and unnatural cannabinoid derivatives. This is a true breakthrough.”

Renew Biopharma (www.RenewBiopharma.com) focuses its work on neuroinflammation pathologies and chronic pain management. Based in San Diego, Renew’s novel molecules are derivatives of cannabinoid molecules that naturally cross the blood-brain barrier. The company develops its molecules in the lab without relying on the use of Cannabis plants. The company’s portfolio of intellectual property includes more than 40 assigned and issued patents, including dominating intellectual property to control key enzymes for biosynthesis and improvement of cannabinoid molecules in microbes.

Forward-looking Statements:

This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All included statements, other than statements of historical facts, regarding strategy, future operations, prospects, plans and objectives of management are forward-looking statements. In some cases, you can identify these statements by forward-looking words such as “may,” “will,” “continue,” “anticipate,” “intend,” “could,” “project,” “seek,” “expect” or the negative or plural of these words or similar expressions. Examples of such statements include, but are not limited to, statements relating to whether the activities of the company result in potential therapeutics, our ability to use or expand our technology platforms, our ability to identify and build a pipeline of product candidates, size of market, our ability to obtain and adequately protect intellectual property rights. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. You should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Except as otherwise required by law, all parties disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Contacts

Larry Shushan
Renew Biopharma

510-701-6920

Source: https://www.businesswire.com/news/home/20191001005416/en/Renew-Biopharma-Announces-Landmark-Patent-Cannabinoid-Biosynthesis

0
Avatar

Press Release

Click here to join our weekly newsletter. We want to hear what you think about this article. Got a tip for our news team? Write to editorial@synbiobeta.com.

Editor’s picks